Wedbush Maintains Neutral on Karyopharm Therapeutics, Lowers Price Target to $4
Portfolio Pulse from richadhand@benzinga.com
Wedbush analyst David Nierengarten has maintained a Neutral rating on Karyopharm Therapeutics (NASDAQ:KPTI) and lowered the price target from $7 to $4.
July 26, 2023 | 12:39 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Wedbush has maintained a Neutral rating on Karyopharm Therapeutics and lowered the price target from $7 to $4.
The lowering of the price target by Wedbush from $7 to $4 indicates a negative outlook for Karyopharm Therapeutics. This could potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100